Outcomes19

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

1 to 19 of 19

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Plan A - Percentage of Participants Achieving Overall Response	Baseline, Week 16	Full Analysis Set (FAS)	Participants	COUNT_OF_PARTICIPANTS
PRIMARY	Plan B - Percentage of Participants Achieving Response in Reduction of Proptosis	Baseline, Week 16	Full Analysis Set (FAS). Due to premature study discontinuation, only Plan A was conducted (no data collected for Plan B, as Plan B was not initiated).
SECONDARY	Plan A - Percentage of Participants Achieving Response in Reduction of Clinical Activity Score (CAS)	Baseline, Week 16	Full Analysis Set (FAS)	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Plan A - Percentage of Participants Achieving Response in Reduction of Proptosis	Baseline, Week 16	Full Analysis Set (FAS)	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Plan A - Percentage of Participants Achieving Response in Diplopia	Baseline, Week 16	Full Analysis Set (FAS)	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Plan A - Mean Change From Baseline to Week 16 in Clinical Activity Score (CAS) in the Study Eye	Baseline, Week 2, Week 4, Week 8, Week 12, Week 16	Full Analysis Set (FAS). Only participants with a value at both Baseline and post-baseline visit included.	Unit on a scale	MEAN
SECONDARY	Plan A - Mean Change From Baseline to Week 16 in Millimeters (mm) of Proptosis in the Study Eye	Baseline, Week 2, Week 4, Week 8, Week 12, Week 16	Full Analysis Set (FAS). Only participants with a value at both Baseline and post-baseline visit included.	millimeters (mm)	MEAN
SECONDARY	Plan A - Percentage of Participants With Improvement in EUGOGO Disease Severity	Baseline, Week 2, Week 4, Week 8, Week 12, Week 16	Full Analysis Set (FAS). Only participants with a value at both Baseline and post-baseline visit included.	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Plan A - Graves' Ophthalmopathy Quality of Life Questionnaire (GO-QOL) Score (Score 1: Visual Functioning) Over Time	Baseline, Week 2, Week 4, Week 8, Week 12, Week 16	Full Analysis Set (FAS). Only participants with a value at both Baseline and post-baseline visit included.	Unit on a scale	MEAN
SECONDARY	Plan A - Graves' Ophthalmopathy Quality of Life Questionnaire (GO-QOL) Score (Score 2: Psychosocial Functioning) Over Time	Baseline, Week 2, Week 4, Week 8, Week 12, Week 16	Full Analysis Set (FAS). Only participants with a value at both Baseline and post-baseline visit included.	Unit on a scale	MEAN
SECONDARY	Plan A - Number of Participants With Adverse Events	From first dose of study treatment until Week 16	Safety Analysis Set (SAF)	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Plan B - Percentage of Participants Achieving Response in Reduction of Clinical Activity Score (CAS)	Baseline, Week 16	Full Analysis Set (FAS). Due to premature study discontinuation, only Plan A was conducted (no data collected for Plan B, as Plan B was not initiated).
SECONDARY	Plan B - Percentage of Participants Achieving Overall Response	Baseline, Week 16	Full Analysis Set (FAS). Due to premature study discontinuation, only Plan A was conducted (no data collected for Plan B, as Plan B was not initiated).
SECONDARY	Plan B - Percentage of Participants Achieving Response in Diplopia	Baseline, Week 16	Full Analysis Set (FAS). Due to premature study discontinuation, only Plan A was conducted (no data collected for Plan B, as Plan B was not initiated).
SECONDARY	Plan B - Mean Change From Baseline to Week 16 in Clinical Activity Score (CAS) in the Study Eye.	Baseline, Week 16	Full Analysis Set (FAS). Due to premature study discontinuation, only Plan A was conducted (no data collected for Plan B, as Plan B was not initiated).
SECONDARY	Plan B - Mean Change From Baseline to Week 16 in Proptosis in the Study Eye.	Baseline, Week 16	Full Analysis Set (FAS). Due to premature study discontinuation, only Plan A was conducted (no data collected for Plan B, as Plan B was not initiated).
SECONDARY	Plan B - Mean Change From Baseline to Week 16 in the Graves' Ophthalmopathy Quality of Life Questionnaire (GO-QOL) Score (Score 1: Visual Functioning)	Baseline, Week 2, Week 4, Week 8, Week 12, Week 16	Full Analysis Set (FAS). Due to premature study discontinuation, only Plan A was conducted (no data collected for Plan B, as Plan B was not initiated).
SECONDARY	Plan B - Mean Change From Baseline to Week 16 in the Graves' Ophthalmopathy Quality of Life Questionnaire (GO-QOL) Score (Score 2: Psychosocial Functioning)	Baseline, Week 2, Week 4, Week 8, Week 12, Week 16	Full Analysis Set (FAS). Due to premature study discontinuation, only Plan A was conducted (no data collected for Plan B, as Plan B was not initiated).
SECONDARY	Plan B - Number of Participants With Adverse Events	From first dose of study treatment until Week 16	Safety Analysis Set (SAF). Due to premature study discontinuation, only Plan A was conducted (no data collected for Plan B, as Plan B was not initiated).

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04737330/outcomes

API reference For AI assistants